Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering where Immunome’s next oncology breakthrough or cash-runway update is hiding? Investors usually start with the 10-K, but the real story stretches across dozens of documents—R&D line items in the Immunome annual report 10-K simplified, follow-up trial costs in each Immunome quarterly earnings report 10-Q filing, and sudden partnership news inside an Immunome 8-K material events explained. Our SEC filings hub guides that journey, so you never miss a data point that can move a biotech valuation overnight.
Stock Titan layers AI-powered summaries on every form, translating dense clinical jargon into plain language. Need the latest Immunome insider trading Form 4 transactions? You’ll get real-time alerts plus AI context on why an executive bought shares ahead of a Phase 1 read-out. Comparing cash burn quarter-over-quarter? Our engine highlights the exact footnotes in the 10-Q. Curious about governance? The Immunome proxy statement executive compensation is annotated so you can see how option grants align with milestone dates.
Because early-stage biotech moves fast, we update seconds after EDGAR posts—whether it’s a license amendment in an 8-K or new Immunome executive stock transactions Form 4. Each filing page answers common questions investors type every day: “Immunome SEC filings explained simply,” “understanding Immunome SEC documents with AI,” and “Immunome earnings report filing analysis.” Stop scrolling through PDFs; start making decisions with AI insights, insider-trade tracking, and the complete archive of Immunome disclosures in one place.
Immunome (IMNM) reported Q3 2025 results showing a net loss of $57.5 million as collaboration revenue dropped to zero after its AbbVie agreement terminated in July 2025. Operating expenses rose to $60.1 million, driven by research and development of $49.2 million and general and administrative of $10.9 million.
Cash and cash equivalents were $272.6 million at September 30, 2025, up from $143.4 million at year-end, reflecting a January 2025 public offering and sales under its at-the-market program. Total liabilities were $35.5 million and stockholders’ equity was $263.9 million. The company states its cash is sufficient to fund operations for at least 12 months from the filing date.
Year to date, net loss improved to $142.5 million from $212.7 million in 2024 as in‑process R&D charges subsided. In January 2025, Immunome issued 22,258,064 shares for net proceeds of $161.7 million. During Q3 2025 it sold 4,625,156 shares via ATM for gross proceeds of $45.9 million; $134.1 million capacity remained at quarter end. Common shares outstanding were 91,710,277 as of November 3, 2025. The pipeline advanced with a Phase 3 trial of varegacestat (topline data expected in the second half of 2025) and ongoing early-stage programs.
Immunome (IMNM) filed an 8-K announcing third-quarter results. The company reported its financial results for the quarter ended September 30, 2025 and provided a business update via a press release furnished as Exhibit 99.1.
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition). The press release is furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated into other SEC filings unless expressly referenced. The filing also lists the Inline XBRL cover page as Exhibit 104.
FMR LLC and Abigail P. Johnson report beneficial ownership of 13,056,709.11 shares of Immunome Inc. common stock, representing
Insider transaction summary for Immunome, Inc. (IMNM): Reporting person Jack Higgins, identified as an officer with the title Chief Scientific Officer, reported transactions dated 09/10/2025. He acquired 22,000 common shares by exercise/transaction code M at a price of $1.35 per share, bringing his reported direct beneficial ownership in common stock to 40,729 shares. The filing also reports derivative holdings: an employee stock option with a conversion/exercise price of $1.35 exercisable beginning 06/23/2032 and, following the reported transactions, 151,840 derivative securities are shown as beneficially owned. Vesting terms state 25% vested on 05/01/2023 with the remainder vesting in 36 equal monthly installments.
Immunome, Inc. (IMNM) – Form 4 insider filing
Chief Technical Officer Philip Tsai was granted an employee stock option for 190,000 common shares on 29-Jul-2025 at an exercise price of $10.60. The options expire on 28-Jul-2035. No common shares were bought, sold or otherwise transferred in the filing; the entire award is reported as directly owned.
Vesting schedule: 25 % of the grant vests on 29-Jul-2026; the remaining 75 % vests in 36 equal monthly installments thereafter. Following this grant, Tsai beneficially owns 190,000 derivative securities (options) and no change to his non-derivative share count is disclosed.
The transaction is a routine equity incentive meant to align executive interests with shareholders. Dilution will only occur if the options are exercised at prices above $10.60.
Immunome Inc. (IMNM) filed a Form 4 for Chief Medical Officer Dr. Robert Lechleider, reporting the grant of 242,000 employee stock options on 07/29/2025. The options carry a $10.60 exercise price and expire on 07/28/2035. Vesting terms: 25 % on 07/29/2026, then monthly vesting of the remaining 75 % over 36 months, leading to full vesting by 07/29/2029. After the award, the CMO beneficially owns 242,000 derivative securities; no common-stock holdings or open-market trades were disclosed. The transaction is coded “A” (grant) and is held directly; no 10b5-1 plan was indicated. The filing represents standard incentive compensation with no immediate share dilution or cash impact for investors.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
